|
Aug 5
|
Here's Why Momentum in UCB (UCBJY) Should Keep going
|
|
Aug 5
|
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 18
|
Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth
|
|
Jul 14
|
UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jun 27
|
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
|
|
Mar 7
|
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
|
|
Mar 7
|
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
|
|
Mar 7
|
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
|
|
Oct 11
|
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Jul 29
|
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
|
|
Jul 29
|
Prio And Two Other Stocks That May Be Priced Below Their Estimated Value
|
|
Jun 18
|
Top Value Stocks That Could Be Bargains In June 2024
|
|
Jun 13
|
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
|
|
Apr 4
|
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
|
|
Dec 2
|
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
|
|
Dec 1
|
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
|
|
Oct 12
|
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
|